Prevent the Preventable

Patient safety is the utmost importance to you. We understand. It is for us too. Quantitative Neuromuscular Blockade Monitoring augments your clinical expertise and provides unwavering confidence in clinical decision making from start to finish.

Senzime´s innovative device, TetraGraph®, supports the optimization of patient management in patients receiving neuromuscular blocking agents (NMBAs). TetraGraph® can be used from start to finish during the surgical procedure. The quantitative monitor enables objective assessment of the depth of block and titration of medication dosage to help determine when the patient has recovered sufficiently to maintain spontaneous breathing.

Senzime, Inc. is located in Naples, Florida.

Residual Neuromuscular Blockade

Qualitative vs Quantitative Monitoring


The new Gold Standard


2021-11-25 09:00
Nomination Committee in Senzime ahead of the 2022 Annual General Meeting

2021-11-12 08:45
Interim report January - September 2021

2021-10-15 09:05
Senzime reports TetraGraph highlights from the American Society of Anesthesiologists Annual Meeting

See all »